Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG.

N Engl J Med. 2003 Mar 27;348(13):1201-14.

2.

FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.

Wang LN, Pan Q, Fu JF, Shi JY, Jin J, Li JM, Hu J, Zhao WL, Chen Z, Chen SJ.

Chin Med J (Engl). 2008 May 20;121(10):867-73.

PMID:
18706197
3.

Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome.

Stone RM, Gilliland DG, Klion AD.

Semin Oncol. 2004 Apr;31(2 Suppl 6):12-7. Review.

PMID:
15175999
4.

The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.

Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutré SE.

Blood. 2004 Apr 15;103(8):2879-91. Epub 2003 Nov 20. Review.

5.

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.

Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A.

Blood. 2003 Nov 1;102(9):3093-6. Epub 2003 Jul 3.

6.

Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.

Roche-Lestienne C, Lepers S, Soenen-Cornu V, Kahn JE, Laï JL, Hachulla E, Drupt F, Demarty AL, Roumier AS, Gardembas M, Dib M, Philippe N, Cambier N, Barete S, Libersa C, Bletry O, Hatron PY, Quesnel B, Rose C, Maloum K, Blanchet O, Fenaux P, Prin L, Preudhomme C.

Leukemia. 2005 May;19(5):792-8.

PMID:
15772698
7.

The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.

Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG.

Curr Opin Hematol. 2004 Jan;11(1):51-7. Review.

PMID:
14676627
8.

Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia.

Score J, Curtis C, Waghorn K, Stalder M, Jotterand M, Grand FH, Cross NC.

Leukemia. 2006 May;20(5):827-32.

PMID:
16498388
9.

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.

Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, de Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, Martinelli G.

Haematologica. 2007 Sep;92(9):1173-9. Epub 2007 Aug 1.

10.

The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.

La Starza R, Specchia G, Cuneo A, Beacci D, Nozzoli C, Luciano L, Aventin A, Sambani C, Testoni N, Foppoli M, Invernizzi R, Marynen P, Martelli MF, Mecucci C.

Haematologica. 2005 May;90(5):596-601.

11.

A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.

Helbig G, Stella-Hołowiecka B, Majewski M, Całbecka M, Gajkowska J, Klimkiewicz R, Moskwa A, Grzegorczyk J, Lewandowska M, Hołowiecki J.

Br J Haematol. 2008 Apr;141(2):200-4. doi: 10.1111/j.1365-2141.2008.07033.x. Epub 2008 Feb 26.

PMID:
18307562
12.

A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.

Salemi S, Yousefi S, Simon D, Schmid I, Moretti L, Scapozza L, Simon HU.

Allergy. 2009 Jun;64(6):913-8. doi: 10.1111/j.1398-9995.2009.01943.x. Epub 2009 Feb 7.

13.

[The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].

Li B, Zhang GS, Dai CW, Pei MF.

Zhonghua Yi Xue Za Zhi. 2005 Feb 23;85(7):448-52. Chinese.

PMID:
15854548
14.

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.

Lierman E, Folens C, Stover EH, Mentens N, Van Miegroet H, Scheers W, Boogaerts M, Vandenberghe P, Marynen P, Cools J.

Blood. 2006 Aug 15;108(4):1374-6. Epub 2006 Apr 27.

15.

[A man with oral ulcers caused by hypereosinophilic syndrome and a good response to the tyrosine-kinase inhibitor imatinib].

Verstappen MC, Mattijssen V, van der Reijden BA, van der Heijden AJ, Wahab PJ, de Vries RA.

Ned Tijdschr Geneeskd. 2006 May 27;150(21):1188-92. Dutch.

PMID:
16768284
16.

[Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib].

Wolf D, Gastl G, Rumpold H.

Dtsch Med Wochenschr. 2004 Oct 1;129(40):2104-6. German.

PMID:
15455302
17.
18.

[Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].

Menif S, Ben Romdhane N, Hafsia R.

Rev Med Interne. 2008 Jan;29(1):65-7. Epub 2007 Oct 25. French.

PMID:
18036706
19.

Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.

Coutré S, Gotlib J.

Semin Cancer Biol. 2004 Aug;14(4):307-15. Review.

PMID:
15305431
20.

Response to imatinib mesylate in patients with hypereosinophilic syndrome.

Arefi M, García JL, Briz MM, de Arriba F, Rodríguez JN, Martín-Núñez G, Martínez J, López J, Suárez JG, Moreno MJ, Merino MA, Gutiérrez NC, Hernández-Rivas JM.

Int J Hematol. 2012 Sep;96(3):320-6. doi: 10.1007/s12185-012-1141-7. Epub 2012 Jul 18.

PMID:
22806436
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk